| The HER2-low revolution in breast oncology: steps forward and emerging challenges E Nicolò, L Boscolo Bielo, G Curigliano, P Tarantino Therapeutic Advances in Medical Oncology 15, 17588359231152842, 2023 | 23 | 2023 |
| Variant allele frequency: a decision-making tool in precision oncology? LB Bielo, D Trapani, M Repetto, E Crimini, C Valenza, C Belli, ... Trends in Cancer 9 (12), 1058-1068, 2023 | 17 | 2023 |
| Targeting cellular components of the tumor microenvironment in solid malignancies C Belli, G Antonarelli, M Repetto, L Boscolo Bielo, E Crimini, G Curigliano Cancers 14 (17), 4278, 2022 | 14 | 2022 |
| The return of RET GateKeeper mutations? an in-silico exploratory analysis of potential resistance mechanisms to novel RET macrocyclic inhibitor TPX-0046 M Repetto, E Crimini, L Ascione, L Boscolo Bielo, C Belli, G Curigliano Investigational new drugs 40 (5), 1133-1136, 2022 | 12 | 2022 |
| Antibody-drug conjugates in breast cancer: what is beyond HER2? E Nicolò, M Repetto, LB Bielo, P Tarantino, G Curigliano The Cancer Journal 28 (6), 436-445, 2022 | 7 | 2022 |
| Future potential targets of antibody-drug conjugates in breast cancer C Corti, LB Bielo, AC Schianca, BT Salimbeni, C Criscitiello, G Curigliano The Breast 69, 312-322, 2023 | 5 | 2023 |
| Molecular tumour board at European Institute of Oncology: report of the first three year activity of an Italian precision oncology experience M Repetto, E Crimini, LB Bielo, E Guerini-Rocco, L Ascione, A Bonfanti, ... European Journal of Cancer 183, 79-89, 2023 | 5 | 2023 |
| Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer L Cantini, D Trapani, L Guidi, LB Bielo, R Scafetta, M Koziej, L Vidal, ... Cancer Treatment Reviews, 102669, 2023 | 3 | 2023 |
| Postneoadjuvant treatment for triple-negative breast cancer D Trapani, E Ferraro, F Giugliano, LB Bielo, G Curigliano, HJ Burstein Current Opinion in Oncology 34 (6), 623-634, 2022 | 3 | 2022 |
| Pharmacoeconomics of novel pharmacotherapies in triple-negative breast cancer L Boscolo Bielo, D Trapani, G Curigliano Expert Opinion on Pharmacotherapy 24 (7), 789-801, 2023 | 2 | 2023 |
| Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents E Nicolò, P Tarantino, O D’Ecclesiis, G Antonarelli, L Boscolo Bielo, ... The Oncologist 29 (1), 75-83, 2024 | 1 | 2024 |
| HER2-positive breast cancer: cotargeting to overcome treatment resistance P Zagami, LB Bielo, E Nicolò, G Curigliano Current Opinion in Oncology 35 (6), 461-471, 2023 | 1 | 2023 |
| Treatment optimization in early triple negative breast cancer E Kotteas, LB Bielo, C Valenza, C Santoro, C Koukoutzeli, D Trapani, ... Expert review of anticancer therapy 23 (10), 1107-1116, 2023 | 1 | 2023 |
| Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis … C Valenza, D Trapani, S Gandini, C Sposetti, LB Bielo, A Marra, ... European Journal of Cancer 190, 112944, 2023 | 1 | 2023 |
| Cancers of Unknown Primary Origin: Real-World Clinical Outcomes and Genomic Analysis at the European Institute of Oncology L Boscolo Bielo, C Belli, E Crimini, M Repetto, L Ascione, G Pellizzari, ... The Oncologist 29 (6), 504-510, 2024 | | 2024 |
| The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast Cancer LB Bielo, D Trapani, E Nicolò, C Valenza, L Guidi, C Belli, E Kotteas, ... Cancer Treatment Reviews, 102761, 2024 | | 2024 |
| Abstract PO1-06-04: Immune checkpoint inhibitors for triple-negative inflammatory breast cancer (INCORPORATE): an international multicenter retrospective analysis C Valenza, D Trapani, P Zagami, G Antonarelli, LB Bielo, E Nicolò, ... Cancer Research 84 (9_Supplement), PO1-06-04-PO1-06-04, 2024 | | 2024 |
| 35P Genomic and clinical landscape of metastatic hormone receptor-positive breast cancers carrying ESR1 alterations LB Bielo, EG Rocco, D Trapani, P Zagami, BT Salimbeni, A Esposito, ... ESMO Open 9, 2024 | | 2024 |
| 246P Clinical utility of molecular tumor board in metastatic breast cancer A Marra, LB Bielo, E Crimini, M Repetto, M Barberis, M Lombardi, ... ESMO Open 9, 2024 | | 2024 |
| 98P Cancers of unknown primary (CUP): Real-world clinical outcomes and genomic analysis at the European Institute of Oncology LB Bielo, C Belli, E Crimini, M Repetto, EG Rocco, L Ascione, C Santoro, ... ESMO Open 9, 2024 | | 2024 |
